Fucosylated C4b-binding protein [alpha]-chain, a novel serum biomarker that predicts lymph node metastasis in pancreatic ductal adenocarcinoma

C4b-binding protein [alpha]-chain (C4BPA) was previously identified as a novel serum biomarker for pancreatic ductal adenocarcinoma (PDAC). To apply this biomarker for clinical diagnosis, a lectin ELISA was established to measure serum fucosylated (Fuc)-C4BPA levels in 45 patients with PDAC, 20 pati...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2021-02, Vol.21 (2), p.1
Main Authors: Sogawa, Kazuyuki, Yamanaka, Sakino, Takano, Shigetsugu, Sasaki, Kosuke, Miyahara, Yoji, Furukawa, Katsunori, Takayashiki, Tsukasa, Kuboki, Satoshi, Takizawa, Hirotaka, Nomura, Fumio, Ohtsuka, Masayuki
Format: Article
Language:English
Subjects:
Adenocarcinoma
Analysis
CEA (Oncology)
Enzyme-linked immunosorbent assay
Lectins
Metastasis
Pancreatic cancer
Pancreatitis
Protein binding
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:C4b-binding protein [alpha]-chain (C4BPA) was previously identified as a novel serum biomarker for pancreatic ductal adenocarcinoma (PDAC). To apply this biomarker for clinical diagnosis, a lectin ELISA was established to measure serum fucosylated (Fuc)-C4BPA levels in 45 patients with PDAC, 20 patients with chronic pancreatitis (CP) and 50 healthy volunteers (HVs) in one training and three validation sets. The lecithin ELISA developed in the current study exhibited satisfactory within-run (2.6-6.7%) and between-day (1.8-3.6%) coefficient of variations. Serum Fuc-C4BPA levels in patients with PDAC (0.54[+ or -]0.27 AU/ml) was significantly higher than that in HVs (0.21[+ or -]0.06 AU/ml; P
ISSN:1792-1074
DOI:10.3892/ol.2020.12388